You are in: eMedicine Specialties > Dermatology > REACTIVE AND INFLAMMATORY DERMATOSES Transient Acantholytic DermatosisArticle Last Updated: Feb 22, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Edward J Zabawski Jr, DO, RPh, Dermatology, Spencer Dermatology Group, Crawfordsville, Indiana Coauthor(s): Clay J Cockerell, MD, Director, Clinical Professor, Department of Dermatology, Division of Dermatopathology, University of Texas Southwestern Medical Center Editors: Donald Belsito, MD, Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of Missouri at Kansas City; Private Practice, American Dermatology Associates, LLC; Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA; Julia R Nunley, MD, Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center Author and Editor Disclosure Synonyms and related keywords: Grover disease, pruritic dermatosis INTRODUCTIONBackgroundTransient acantholytic dermatosis is not an uncommon condition, but, surprisingly, it was not thoroughly characterized until Grover did so in 1970. While generally accepted to be a benign, self-limited disorder, it is often persistent and difficult to manage; hence, the description of transient is misleading. The presentation can be subtle, or it may closely resemble other pruritic dermatoses. A high index of suspicion for this disease is necessary if the diagnosis is to be made correctly. Furthermore, the histologic features of Grover disease closely resemble those of several other conditions that are clinically distinct, which may add to potential diagnostic confusion. PathophysiologyThe etiology of Grover disease is unknown. However, a number of factors have been suggested as being potentially causal or exacerbating. The most frequent association is with heat or sweating, and the obstruction of sweat ducts has been postulated to be responsible. Many patients describe preceding exposure to sunlight, although exposure to artificial ultraviolet radiation has not been shown to reproduce the process. Grover disease seems to occur more frequently in patients with atopic dermatitis and asteatotic dermatitis, although many individuals with these conditions never develop it. Viral, bacterial, and other pathogens have also been proposed, but no causative role has been established. The exact pathogenesis has not been elucidated. FrequencyUnited StatesExact numbers regarding the prevalence of the disease are not available. Because of the clinical similarities with other entities and variable histopathologic findings, the disease is underdiagnosed in nondermatologic settings and probably underdiagnosed overall. RaceGrover disease most commonly affects middle-aged white men, although it may be seen in other ethnic groups, such as Hispanics and blacks. SexMen are affected 3 times more often than women. AgeGrover disease most commonly affects middle-aged men; however, it has been in reported in children. CLINICALHistory
Physical
CausesThe etiology of Grover disease is unknown. DIFFERENTIALSDermatitis Herpetiformis Folliculitis Herpes Simplex Herpes Zoster Insect Bites Milia Miliaria Pityriasis Rosea Scabies Syphilis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Isotretinoin (Accutane) |
|---|---|
| Description | Oral agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the naturally occurring tretinoin (trans-retinoic acid). Both agents are structurally related to vitamin A. |
| Adult Dose | 0.5-1 mg/kg/d PO for 2-12 wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; menstruating females at risk of conceiving and all fertile women receiving retinoids; pregnancy |
| Interactions | Toxicity may occur with vitamin A coadministration; pseudotumor cerebri or papilledema may occur when coadministered with tetracyclines; acitretin may reduce plasma levels of carbamazepine |
| Pregnancy | X - Contraindicated; benefit does not outweigh risk |
| Precautions | May decrease night vision; inflammatory bowel disease may occur; may be associated with development of hepatitis; occasional exaggerated healing response of acne lesions (excessive granulation with crusting) may occur; patients with diabetes may experience problems in controlling their blood sugar level while on isotretinoin; avoid exposure to UV light or sunlight until tolerance achieved; discontinue treatment if rectal bleeding, abdominal pain, or severe diarrhea occur; mood swings or depression may occur; caution if history of depression |
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
| Drug Name | Prednisone (Deltasone, Sterapred, Orasone) |
|---|---|
| Description | Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. |
| Adult Dose | 5-60 mg/d PO qd or divided bid/qid; taper over 2 wk as symptoms resolve |
| Pediatric Dose | 4-5 mg/m2/d PO; alternatively, 0.05-2 mg/kg PO divided bid/qid; taper over 2 wk as symptoms resolve |
| Contraindications | Documented hypersensitivity; viral, fungal, connective tissue, or tubercular skin infections; peptic ulcer disease; hepatic dysfunction; GI disease |
| Interactions | Coadministration with estrogens may decrease clearance; when used with digoxin, digitalis toxicity secondary to hypokalemia may increase; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, cataracts, and infections may occur with glucocorticoid use |
These agents regulate cell growth and differentiation.
| Drug Name | Methotrexate (Folex PFS, Rheumatrex) |
|---|---|
| Description | Antimetabolite that inhibits DNA synthesis and cell reproduction in malignant cells. Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). |
| Adult Dose | PO/IV/IM: 0.3 mg/kg/wk; not to exceed 20 mg; administer 7.5-mg test dose and check CBC count and LFTs in 1 wk; if results normal, continue weekly 1-time 7.5-mg doses (may split if GI upset to 8-am, 8-pm, 8-am dosing); increase dose by 2.5 mg/wk each mo; may taper by 2.5 mg/wk each month when decreasing dose to lowest possibility IM: 15-75 mg IM given at 1- 2-wk intervals |
| Pediatric Dose | 5-15 mg/m2/wk PO/IM qd or divided tid given 12 h apart |
| Contraindications | Absolute: Pregnancy or desire to get pregnant; active peptic ulcer; alcoholism; primary/secondary immunodeficiency; blood dyscrasias; active hepatitis; cirrhosis; chronic renal failure; active infections Relative: History of excessive ethanol intake or substance abuse; increased LFT values; recent hepatitis; diabetes; obesity; history of heritable liver disease; unreliable patient; CrCl <50 mL/min; male contemplating conception (must have 3 mo off) |
| Interactions | Salicylates, NSAIDs, dipyridamole, probenecid, retinoids, ethanol, triamterene, pyrimethamine, sulfonamides, TCN, chloramphenicol, penicillin or other broad-spectrum antibiotics, trimethoprim, dapsone, theophylline, phenytoin, phenothiazines, barbiturates and nitrofurantoin (impair folic acid absorption), ascorbic acid, phenylbutazone, cyclosporin, aminoglycosides |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Monitor CBC counts monthly, and liver and renal function q1-3mo during therapy (monitor more frequently during initial dosing, dose adjustments, or when risk of elevated MTX levels, eg, dehydration); has toxic effects on hematologic, renal, GI, pulmonary, and neurologic systems; discontinue if significant decrease in blood counts occurs; aspirin, NSAIDs, or low-dose steroids may be administered concomitantly with MTX (possibility of increased toxicity with NSAIDs, including salicylates, has not been tested) |
| Media file 1: A 54-year-old man with a pruritic eruption on the trunk. Notice the slight lichenification and significant erythema from rubbing that is localized to the central part of the torso. Also note the red-brown papules in the abdominal region. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Closer view of the abdominal area (same patient as in Media File 1). Multiple, small, discrete, red-brown papules characteristic of Grover disease are present. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Histopathology of Darier-type Grover disease. A focus of acantholytic dyskeratosis is present in the epidermis with slight epithelial hyperplasia and hyperkeratosis, a sign of rubbing as a consequence of the pruritic nature of the disease (hematoxylin and eosin, original magnification X40). | |
![]() | View Full Size Image | Media type: Photo |
| Media file 4: Higher magnification reveals the acantholytic dyskeratosis to better advantage. Note the corps ronds and grains (hematoxylin and eosin, original magnification X400). | |
![]() | View Full Size Image | Media type: Photo |
Transient Acantholytic Dermatosis excerpt
Article Last Updated: Feb 22, 2007